| Today's Open | $0.56 |
|---|---|
| Previous Close | $0.57 |
| Daily Range | $0.55 - $0.57 |
| 52-Week Range | $0.52 - $2.35 |
| Market Cap | $25.6M |
| P/E Ratio | -0.63 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 363,421 |
| Average Daily Volume | 270,313 |
| Current FY EPS | -$0.54 |
Sector
Healthcare
Industry
Drugs
AASTROM BIOSCIENCES, INC. (ASTM) Description
The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology. Website: http://www.aastrom.com/
News & Commentary
Aastrom Biosciences Finds a CEO
Dan Orlando stops being interim CEO, as Dominick Colangelo arrives to take charge.Aastrom Biosciences Says First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel
Aastrom Biosciences Says First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-TMarket Close: Big Winners & Losers for March 27, 2013 (CHCI, RDHL, UEPS, RVLT, LIVE, ASTM, EVBS, ISN
Market Close: Big Winners & Losers for March 27, 2013 (CHCI, RDHL, UEPS, RVLT, LIVE, ASTM, EVBS, ISNS, ATOS, GV)Oppenheimer Reiterates Perform Rating on Aastrom Biosciences on Discontinuation of Phase III REVIVE
Oppenheimer Reiterates Perform Rating on Aastrom Biosciences on Discontinuation of Phase III REVIVE CLIASTM's Top Competitors
(-1.75%)
(1.04%)
(-0.80%)
(-0.19%)